Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Latent Expression of the Epstein-Barr Virus (EBV)-Encoded Major Histocompatibility Complex Class I TAP Inhibitor, BNLF2a , in EBV-Positive Gastric Carcinomas

15 Jul 2015

Abstract excerpt

The Epstein-Barr virus (EBV) BNLF2a gene product provides immune evasion properties to infected cells through inhibition of transporter associated with antigen processing (TAP)-mediated transport of antigen peptides. Although BNLF2a is considered to be a lytic gene, we demonstrate that it is expressed in nearly half of the EBV-associated gastric carcinomas analyzed. Further, we show that BNLF2a expression is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immune Cell Function and Interaction
Share to Lymphoma Diagnosis and Treatment
Share to Viral-associated cancers and disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26178981
DOI: 10.1128/jvi.01110-15

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Latent Expression of the Epstein-Barr Virus (EBV)-Encoded Major Histocompatibility Complex Class I TAP Inhibitor, BNLF2a , in EBV-Positive Gastric CarcinomasPMID 26178981Read ↗

Specific Targeting of the EBV Lytic Phase Protein BNLF2a to the Transporter Associated with Antigen Processing Results in Impairment of HLA Class I-Restricted Antigen PresentationSemantic proximity Read ↗

Stage-specific inhibition of MHC class I presentation by the Epstein-Barr virus BNLF2a protein during virus lytic cycle.Semantic proximity Read ↗

Epstein-Barr virus isolates retain their capacity to evade T cell immunity through BNLF2a despite extensive sequence variation.Semantic proximity Read ↗

High MHC-II expression in Epstein–Barr virus-associated gastric cancers suggests that tumor cells serve an important role in antigen presentationSemantic proximity Read ↗

Sequence analysis of EBV immune evasion gene BNLF2a in EBV associated tumors and healthy individuals from nasopharyngeal carcinoma endemic and non-endemic regions of China.Semantic proximity Read ↗

The effects of the Epstein-Barr virus latent membrane protein 2A on B cell function.Semantic proximity Read ↗

Impaired Transporter Associated with Antigen Processing-Dependent Peptide Transport during Productive EBV InfectionSemantic proximity Read ↗

Identification of a TAP-Independent, Immunoproteasome-Dependent CD8<sup>+</sup>T-Cell Epitope in Epstein-Barr Virus Latent Membrane Protein 2Semantic proximity Read ↗

Latent Membrane Protein LMP2A Impairs Recognition of EBV-Infected Cells by CD8+ T CellsSemantic proximity Read ↗

Sequence variations of Epstein-Barr virus LMP2A gene in gastric carcinoma in Japan.Semantic proximity Read ↗

A CD8+ T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primatesSemantic proximity Read ↗

Expression of Epstein-Barr virus genes in EBV-associated gastric carcinomasSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.